Log In
Print
BCIQ
Print
Print this Print this
 

CVT-301

  Manage Alerts
Collapse Summary General Information
Company Civitas Therapeutics Inc.
DescriptionInhaled formulation of levodopa delivered via Civitas' Arcus inhalation technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat motor fluctuations associated with Parkinson's disease (PD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today